EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Integrative metabolomics science in Alzheimer’s disease: Relevance and future perspectives

Simone Lista, Raúl González-Domínguez, Susana López-Ortiz, Álvaro González-Domínguez, Héctor Menéndez, Juan Martín-Hernández, Alejandro Lucia, Enzo Emanuele, Diego Centonze, Bruno P Imbimbo, Viviana Triaca, Luana Lionetto und 7 weitere

Ageing Research Reviews · 2023-08 · 89 · 101987

DOI: 10.1016/j.arr.2023.101987 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2023-08. Verfasst von Simone Lista und 18 weiteren Autor:innen. Beteiligte Einrichtung: i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), Valladolid, Spain. Electronic addre…. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 312 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institutes of Health, Wisconsin Alumni Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is determined by various pathophysiological mechanisms starting 10-25 years before the onset of clinical symptoms. As multiple functionally interconnected molecular/cellular pathways appear disrupted in AD, the exploitation of high-throughput unbiased omics sciences is critical to elucidating the precise pathogenesis of AD. Among different omics, metabolomics is a fast-growing discipline allowing for the simultaneous detection and quantification of hundreds/thousands of perturbed metabolites in tissues or biofluids, reproducing the fluctuations of multiple networks affected by a disease. Here, we seek to critically depict the main metabolomics methodologies with the aim of identifying new potential AD biomarkers and further elucidating AD pathophysiological mechanisms. From a systems biology perspective, as metabolic alterations can occur before the development of clinical signs, metabolomics - coupled with existing accessible biomarkers used for AD screening and diagnosis - can support early disease diagnosis and help develop individualized treatment plans. Presently, the majority of metabolomic analyses emphasized that lipid metabolism is the most consistently altered pathway in AD pathogenesis. The possibility that metabolomics may reveal crucial steps in AD pathogenesis is undermined by the difficulty in discriminating between the causal or epiphenomenal or compensatory nature of metabolic findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansMetabolomicsMetabolomeBiomarkers

Stichwörter der Autor:innen

Alzheimer’s diseaseAmino acidsBiomarkersLipidsMetabolomicsSystems biology

Substanzen

Biomarkers

Autor:innen und Institutionen

  • i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), Valladolid, Spain. Electronic address: slista@uemc.es.
  • Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), Hospital Universitario Puerta del Mar, Universidad de Cádiz, Cádiz, Spain.
  • i+HeALTH Strategic Research Group, Department of Health Sciences, Miguel de Cervantes European University (UEMC), Valladolid, Spain.
  • Research Institute of the Hospital 12 de Octubre ('imas12'), Madrid, Spain; Faculty of Sport Sciences, European University of Madrid, Villaviciosa de Odón, Madrid, Spain; CIBER of Frailty and Healthy Ageing (CIBERFES),…
  • 2E Science, Robbio, Pavia, Italy.
  • Department of Systems Medicine, Tor Vergata University, Rome, Italy; Unit of Neurology, IRCCS Neuromed, Pozzilli, IS, Italy.

Förderung

  • NIA NIH HHS
  • National Institutes of Health
  • Wisconsin Alumni Research Foundation
  • University of Wisconsin-Madison
  • Instituto de Salud Carlos III

Zitieren

APA

Lista, S., González-Domínguez, R., López-Ortiz, S., González-Domínguez, Á., Menéndez, H., Martín-Hernández, J., Lucia, A., Emanuele, E., Centonze, D., Imbimbo, B. P., Triaca, V., Lionetto, L., Simmaco, M., Cuperlovic-Culf, M., Mill, J., Li, L., Mapstone, M., Santos-Lozano, A., & Nisticò, R. (2023). Integrative metabolomics science in Alzheimer’s disease: Relevance and future perspectives. Ageing Research Reviews, 89, 101987. https://doi.org/10.1016/j.arr.2023.101987

Vancouver

Lista S, González-Domínguez R, López-Ortiz S, González-Domínguez Á, Menéndez H, Martín-Hernández J, et al. Integrative metabolomics science in Alzheimer’s disease: Relevance and future perspectives. Ageing Research Reviews. 2023;89:101987. doi:10.1016/j.arr.2023.101987

BibTeX
@article{Lista2023,
  author = {Lista, Simone and González-Domínguez, Raúl and López-Ortiz, Susana and González-Domínguez, Álvaro and Menéndez, Héctor and Martín-Hernández, Juan and Lucia, Alejandro and Emanuele, Enzo and Centonze, Diego and Imbimbo, Bruno P and Triaca, Viviana and Lionetto, Luana and Simmaco, Maurizio and Cuperlovic-Culf, Miroslava and Mill, Jericha and Li, Lingjun and Mapstone, Mark and Santos-Lozano, Alejandro and Nisticò, Robert},
  title = {Integrative metabolomics science in Alzheimer’s disease: Relevance and future perspectives},
  journal = {Ageing Research Reviews},
  year = {2023},
  volume = {89},
  pages = {101987},
  doi = {10.1016/j.arr.2023.101987}
}
Kostenlos starten →